Iavi and moderna partner to tackle broad global health priorities using mrna for vaccines and antibodies

Collaboration to target bacterial and viral pathogens including hiv, sars-cov-2, antimicrobial-resistant pathogens, and tuberculosis new york, ny and cambridge, ma / accesswire / april 7, 2022 / moderna, inc., (nasdaq:mrna) a biotechnology company pioneering messenger rna (mrna) therapeutics and vaccines, and the nonprofit scientific research organization iavi today announced a new collaboration to employ mrna technology to meet the challenge of a range of global health threats. these diseases - hiv/aids, tuberculosis (tb), antimicrobial-resistant enteric infections, and covid-19 - are estimated to have caused at least 95 million new infections and more than 4 million deaths in 2020 alone.
MRNA Ratings Summary
MRNA Quant Ranking